New therapy wins EMA orphan drug designation for ALS
August 9, 2016Manufacturing and Production, Research and Development EMA, Ice Bucket Challenge, ab science, als, masitinib, oprhan drug designation
French pharma company AB Science has announced that the European Medicines Agency has granted orphan drug status to masitinib for …
AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again
August 9, 2016Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure
AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …
Management shake-up at Valeant as Papa expands senior team
August 9, 2016Manufacturing and Production, Sales and Marketing Valeant, joseph papa, management, shake up
Joseph Papa continues to remodel the plagued Valeant Pharmaceuticals, as a senior management shake-up has seen several new arrivals and …
FDA approves MSD’s Keytruda for head and neck cancer treatment
August 8, 2016Manufacturing and Production, Research and Development Cancer, FDA, MSD, keytruda
The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab) for treatment of recurrent or metastatic head and …
SMC reverses decision on Opdivo in advanced skin cancer
August 8, 2016Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer
The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …
Apellis Pharmaceuticals appoints Dr Robert Kim as CMO
August 8, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Apellis, CMO, GSK, Novartis, appointment
Clinical stage complement immunotherapy company Apellis Pharmaceuticals has named its new chief medical officer as Dr Robert Kim. Kim’s primary …
AbbVie files lawsuit against Amgen over Humira copy
August 8, 2016Research and Development, Sales and Marketing AbbVie, Amgen, FDA, Humira, rheumatoid arthritis
Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis …
The power of PrEP
August 8, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PrEP, high court, lifestyle drug
Many among the general public may not have heard about PrEP, or pre-exposure prophylaxis, before last week when a high …
Opdivo and Keytruda set for India launches by end of year
August 8, 2016Sales and Marketing India, keytruda, launch, opdivo
Indian cancer patients could be set to receive two of the world’s leading oncology drugs, MSD’s Keytruda and Bristol-Myers Squibb’s …
‘Game changer’ asthma pill sees significant reduction in severe symptoms
August 8, 2016Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, university of Leicester
A study at the University of Leicester has found that Fevipiprant (QAW039), the first new asthma pill for nearly 20 …
MSD files Lantus biosimilar with FDA
August 8, 2016Sales and Marketing FDA, Lantus, MK-1293, MSD, application, biosimilar
MSD, known as Merck in the US and Canada, has filed a new drug application with the US Food and …
Shock for BMS as Opdivo misses goal in late-stage lung cancer trial
August 5, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo
Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …
Top ten stories in the pharmaceutical industry this week
August 5, 2016Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk
August 5, 2016Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure
Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …
Majority of US patients’ groups supporting pharma against Medicare reforms received industry funding, claims report
August 5, 2016Medical Communications, Research and Development medicare reform, patients' groups, public citizen
An overwhelming majority of US patients’ groups who supported the pharmaceutical industry in opposing Medicare part B pricing reforms receive …
Eylea sales jump helps boost Regeneron in Q2 results
August 5, 2016Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results
Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …
NICE recommends Cosentyx in ankylosing spondylitis
August 4, 2016Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis
Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …
Merck Q2 results beat analyst estimates
August 4, 2016Medical Communications, Sales and Marketing Merck, financial results
Germany pharmaceutical firm Merck has announced its fiscal results for Q2 2016, beating analyst estimates with earnings before interest, taxes, …
NIH launches test of investigational human Zika vaccine
August 4, 2016Research and Development Vaccine, Zika virus
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun the clinical …
FDA determines Xiamen Origin Biotech wilfully lied to inspectors and customers
August 4, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Xiamen Origin Biotech
The US Food and Drug Administration (FDA) carried out an inspection of Chinese drug manufacturer Xiamen Origin Biotech, finding the …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
